Hosted on MSN18d
GSK's depemokimab under review in China and Japan for asthma, CRSwNP
Products Administration and submitted to the Japanese Ministry of Health, Labour and Welfare. According to InvestingPro analysis, GSK maintains a "GREAT" financial health score, positioning it ...
GSK launches $2.5 billion buyback, lifts sales target after stellar fourth quarter
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
pharmaphorum15d
GSK's kidney disease anaemia drug approved in Japan, taking on Astellas' rival
In contrast to current standard of care in patients with CKD which requires injections, GSK noted that Duvroq offers convenience with oral administration and flexibility with once-daily dosing ...
Business Insider18d
GSK announces new drug applications accepted for review in China, Japan
GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, Labour and ...
Daily13d
GSK Depemokimab applications accepted for review in China, Japan for asthma with type 2 inflammation, CRSwNP
GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...
The Financial Times9d
GSK is emerging from its long convalescence
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK does not need a miracle cure — just some rest and rehabilitation. Investors, though, seem unwilling ...
Investing18d
GSK's depemokimab under review in China and Japan for asthma, CRSwNP
Products Administration and submitted to the Japanese Ministry of Health, Labour and Welfare. According to InvestingPro analysis, GSK maintains a "GREAT" financial health score, positioning it well ...